A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Effects on Arterial Structure and Function of ACZ885 in Patients With Intermittent Claudication
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Canakinumab (Primary)
- Indications Atherosclerosis
- Focus Therapeutic Use
- Sponsors Novartis
- 21 Jul 2017 Status changed to discontinued based on result from primary endpoint analysis
- 21 Nov 2016 Status changed from recruiting to completed.
- 17 Nov 2016 This trial was discontinued in Germany, according to European Clinical Trials Database.